CIK 0000939767
- Large accelerated filer
EXELIXIS, INC.
Sign in to watch- Ticker
- EXEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Jan 1
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 043257395
- Phone
- +1 650-837-7000
- Business address
- 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502
- Former names
- EXELIXIS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-05-12 | MORRISSEY MICHAEL President and CEO | Shares withheld for taxes | −30,278 | $25.16 | $762K | 511,535 |
| 2021-05-12 | MORRISSEY MICHAEL President and CEO | Exercise or conversion · Option (right to buy) | −50,000 | 100,000 | ||
| 2021-05-11 | Freire Maria C Director | Sale | −8,275 | $25.01 | $207K | 31,827 |
| 2021-05-11 | PAPADOPOULOS STELIOS Director | Exercise or conversion | +40,000 | $6.30 | $252K | 1,228,897 |
| 2021-05-11 | PAPADOPOULOS STELIOS Director | Sale | −10,222 | $24.95 | $255K | 1,218,675 |
| 2021-05-11 | PAPADOPOULOS STELIOS Director | Exercise or conversion | +40,000 | $3.13 | $125K | 1,258,675 |
| 2021-05-11 | PAPADOPOULOS STELIOS Director | Sale | −5,075 | $25.00 | $127K | 1,253,600 |
| 2021-05-11 | PAPADOPOULOS STELIOS Director | Exercise or conversion | +40,000 | $3.38 | $135K | 1,293,600 |
| 2021-05-11 | PAPADOPOULOS STELIOS Director | Sale | −5,473 | $25.01 | $137K | 1,288,127 |
| 2021-05-11 | PAPADOPOULOS STELIOS Director | Exercise or conversion · Option (right to buy) | −40,000 | 0 | ||
| 2021-05-11 | PAPADOPOULOS STELIOS Director | Exercise or conversion · Option (right to buy) | −40,000 | 0 | ||
| 2021-05-11 | PAPADOPOULOS STELIOS Director | Exercise or conversion · Option (right to buy) | −40,000 | 0 | ||
| 2021-05-10 | MORRISSEY MICHAEL President and CEO | Gift | −40,616 | 1,019,067 | ||
| 2021-04-26 | Schwab Gisela Pres, Prod Dev & Med Aff & CMO | Exercise or conversion | +50,000 | $1.70 | $85K | 663,482 |
| 2021-04-26 | Schwab Gisela Pres, Prod Dev & Med Aff & CMO | Sale | −50,000 | $25.00 | $1.3M | 613,482 |
| 2021-04-26 | Schwab Gisela Pres, Prod Dev & Med Aff & CMO | Exercise or conversion · Option (right to buy) | −50,000 | 0 | ||
| 2021-04-26 | Haley Patrick J. EVP, Commercial | Sale | −7,665 | $25.03 | $192K | 297,392 |
| 2021-04-26 | Hessekiel Jeffrey EVP and General Counsel | Sale | −18,000 | $25.03 | $451K | 628,248 |
| 2021-04-01 | Lamb Peter EVP, Scientific Strategy & CSO | Exercise or conversion | +60,000 | $1.70 | $102K | 449,467 |
| 2021-04-01 | Lamb Peter EVP, Scientific Strategy & CSO | Sale | −60,000 | $22.96 | $1.4M | 389,467 |
Page 33 of 42 · 836 trades